medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2016, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2016; 32 (2)

No hodgkin lymphoma Burkitt-like

Quintero-Sierra Y, Hernández-Padrón C

Language: Spanish
References: 14
Page: 265-271
PDF size: 65.29 Kb.


ABSTRACT

The Burkitt-like lymphoma is considered a highly aggressive B-cell lymphoma, with a high proliferative rate. Presentation with extensive mass intestinal involvement is rare and poorly documented in the literature. We report the case of a young adult with the Burkitt-like lymphoma, and presenting extensive infiltration of the right colon, who receives chemotherapy treatment associated with administration of anti-CD20 monoclonal antibody, achieves complete remission of the illness and consolidation with intensive chemotherapy with autologous stem cell transplantation. Currently the patient is asymptomatic and without treatment.


REFERENCES

  1. Conroy SM, Maskarinec G, Morimoto Y, Franke AA, Cooney RV, Wilkens LR, et al. No-Hodgkin Lymphoma and circulating markers of inflammation and adiposity in a nested case-control study: The multiethnic Cohort. Cancer Epidemiol Biomarkers. 2013;22(3):337-47.

  2. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380(9844):848-57.

  3. American Cancer Society: Cancer Facts and Figures 2015. Atlanta, Ga: American Cancer Society, 2015;60(3):664-71.

  4. Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood. 2013;122(6):981-7.

  5. Swedlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA. Classification of Tumours of Haematopoietic and Lymphoid Tissues. Eds. World Health Organization IARC: Lyon; 2008.

  6. Hussong JW, Arber DA, Bradley KT, Brown MS, Chung-Che Ch, David ME, et al. Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms. Arch Pathol Lab Med. 2010;134(6):e40-e47.

  7. Tanaka H, Hashimoto S, Abe D, Sakai S, Takagi T. Double-hit lymphoma at second relapse of Burkitt-like lymphoma: a case report. J Clin Exp Hematop. 2011;51(1):43- 7.

  8. Parker SM, Olteanu H, Vantuinen P, Lawton CA, Schultz CJ, Christians KK, et al. Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. Int J Hematol. 2009;90(5):616-22.

  9. Mocumbi AO, Paul L, Maciel L, Silvia P, Ferreira MB. Secondary intracardiac Burkittlike lymphoma in the absence of HIV infection. Cardiovasc J Afr. 2011;22(2):96-7.

  10. Thomas DA, O'Brien S, Faderl S, Manning JT, Romaguera J, Fayad L, et al. Burkitt Lymphoma and Atipical Burkitt or Burkitt-like Lymphoma: Should These be Treated as Differente Diseases? Curr Hematol Malig Rep. 2011;6(1):58-66.

  11. Kujawski L, Longo WL, Williams EC. High-dose CHOP and midcycle methotrexate for adult Burkitt and Burkitt-like lymphomas. Blood. 2002;100:779a, abstract 3083.

  12. Lacasce A, Howard O, Lib S. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45(4):761-7.

  13. Cabanillas M, Thomas D, Cortes J. Outcome with hyper-CVAD and rituximab in Burkitt (BL) and Burkitt-like (BLL) leukemia/lymphoma. Proc Am Soc Clin Oncol. 2002;106(7):1569-80.

  14. Sweetenham J, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone A. Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma: outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol. 1996;14(9):2465-72.




2020     |     www.medigraphic.com